Results 151 to 160 of about 74,852 (258)

Loss of CHTF18-RFC2/5 leads to replicative gaps and sensitivity to PARP inhibitors. [PDF]

NAR Cancer
Buckley-Benbow L, Ozgencil M, Tardocchi A, Agnarelli A, Bellelli R.   +4 more
europepmc   +1 more source

Transcription–replication conflicts underlie sensitivity to PARP inhibitors

An important advance in cancer therapy has been the development of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of homologous recombination (HR)-deficient cancers 1–6 . PARP inhibitors trap PARPs on DNA.
Petropoulos, Michalis, Freudenmann, Alena, Sotiriou, Sotirios, Iacovino, Luca G., Dionellis, Vasilis, Karamichali, Angeliki, Rossetti, Giacomo, Halazonetis, Thanos   +7 more
core   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

PARP inhibitors in the treatment of ovarian cancer: a narrative review. [PDF]

Transl Cancer Res
Wang Y, Li X, Yang Y, Lv X, Wang K, Li H, Liu X, Jin K, Gao M.   +8 more
europepmc   +1 more source

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer

, 2019
Xuan Jiang, Weihua Li, Xiaoying Li, Huimin Bai, Zhenyu ZhangDepartment of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People’s Republic of ChinaAbstract: Poly (ADP-ribose) polymerase (PARP) inhibitors
Li W, Li X, Zhang Z, Jiang X, Bai H
core  

Mutational Signature‐Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High‐Grade Ovarian Cancer

Cancer Science, EarlyView.
A whole‐exome sequencing–based mutational signature biomarker (MSBM) identified an HRD‐enriched population in advanced ovarian cancer. In a phase II trial, olaparib maintenance suggested clinically meaningful PFS benefit without bevacizumab, supporting MSBM as a complementary HRD assessment approach.
Katsutoshi Oda, Daisuke Shintani, Akira Nishijima, Mayuyo Mori, Kazuyoshi Kato, Shoji Nagao, Noriomi Matsumura, Masahiro Kagabu, Masataka Takenaka, Kosuke Yoshihara, Yosuke Konno, Junzo Hamanishi, Sho Sato, Shiro Takamatsu, Keiko Ueda, Kosuke Kashiwabara, Takashi Aoki, Kunihiro Nishimura, Kenji Tatsuno, Hiroyuki Aburatani, Kosei Hasegawa   +20 more
wiley   +1 more source

Autophagy impairs the sensitivity of Ewing sarcoma cells to PARP inhibitors. [PDF]

Cancer Chemother Pharmacol
Clausen J, Kocher D, Schadwinkel HM, Becker S, Milde T, Beck JF, Sonnemann J.   +6 more
europepmc   +1 more source

Gasdermin‐Mediated Pyroptosis: Novel Strategies Against Colorectal Cancer

Cancer Science, EarlyView.
Pyroptosis is a double‐edged sword in colorectal cancer (CRC): chronic low‐grade pyroptosis promotes tumor progression, whereas acute induction of pyroptosis in cancer cells triggers antitumor immunity and enhances therapeutic response. Targeting gasdermin‐mediated pyroptosis represents a promising strategy for CRC treatment.
Kaibo Guo, Yuqian Feng, Jiamin Lu, Nuerbiye Abudurexiti, Xinlei Zhou, Mengfan Wei, Song Zheng   +6 more
wiley   +1 more source

Development of Mitochondria-Targeted PARP Inhibitors. [PDF]

Biomolecules
Dimitrijevs P, Makrecka-Kuka M, Arsenyan P.   +2 more
europepmc   +1 more source

Targeting Cell Cycle Vulnerabilities in Cancers: Emerging Strategies for Therapeutic Development

Cancer Science, EarlyView.
Dysregulated cell cycle control often involves alternative compensatory pathways in cancers to maintain its robustness but provide unique targetable vulnerabilities. We overview recent insights on cancer‐specific vulnerabilities across the cell cycle and discuss how these can be used to develop new therapeutic strategies.
Nana Kamakura, Minji Jo, Motoko Takahashi, Toru Hirota   +3 more
wiley   +1 more source